Novo Nordisk and MetaVia, Inc. developed dual GLP-1/glucagon receptor agonists.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novo Nordisk and MetaVia, Inc. developed dual GLP-1/glucagon receptor agonists.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- MTVA's novel GPR119 agonist, DA-1241, is being developed in collaboration to expand its therapeutic potential.Sub-event
Novo Nordisk and MetaVia announce joint development of dual GLP-1/glucagon agonists.1 source
Keep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Novo Nordisk received approval in China for Wegovy, while Chinese drugmakers are developing their own GLP-1 medicines.
- Novo Nordisk's Wegovy rollout is planned for Germany as GLP-1 therapies shift consumer priorities.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.
- Viking Therapeutics' GLP-1 results are showing how they stack up against the market leaders, Novo Nordisk and Eli Lilly.
Coverage
Newest first; wire copies grouped- Zacks Small Cap ResearchMTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025… By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1726 48 mg Cohort Study Extended to